1 LINK LUDWIG NOVEMBER 2013 3 |Oxford Report Continued inside > IN THIS ISSUE News from the Ludwig Ludwig the from News scientific retreat A conversation with the the with A conversation 11 | Irv Weissman11 |Irv Q&A Ludwig Stanford director Stanford Ludwig

LUDWIG LINK | NOVEMBER 2013 irector of Communications irector Steinhardt achel positive. more couldn’t have been feedback the nd to the presentations the from was palpable passion he Sincerely, D R Stanford. of Cha Ludwig Adriel said album!” hits greatest of AC/DC’s version biologist’s Itfelt like the labs. Ludwig other with collaborations deeper and new foster to opportunity incredible an me retreat offered “The A thinking. and generate energy, leading to fresh ideas and deeper habits old break can surroundings unfamiliar in being meetings encourage out-of-the-box thinking because Off-site conversations. after-hour and breaks coffee T distinguished researchers from around the world. interactions and collaborations among some of the most to foster opportunity itself.in unparalleled Itwas an was amazing attendees and speakers content, of the LETTER

and networking. The caliber days with information sharing three packed that Oxford in retreat aLudwig note, with high on a off started month last And direction. and thinking new creative in engage and mind the Fall to refresh time isideal an 2 LUDWIG LINK LUDWIG Eats, shoots and leaves and shoots Eats, spliceThe of life Fickle finger of cellfate Sn(i)ps Don’t delete horse Dark beware Buyer News Roundup Well designed Company News Abracadabra to know you Getting Meeting Notes Required Reading Required Weissman with Irv Q&A aScientist Ask TABLE CONTENTS OF of Ludwig Melbourne of Ludwig cover: the Nightingale On Rebecca

NOVEMBER 2013 15 11 10 9 8 7 7 6 5 5 5 4 4 4 3 3

LUDWIG LINK | NOVEMBER 2013 reat innovations often come from group interactions. interactions. group from come often innovations reat “ our about spoke Lane David Director Scientific udwig remarked Notter John Board of the Chairman udwig to opportunity an had community Ludwig entire he “ ahuge was September in Oxford in retreat Ludwig he TO KNOWETTING YOU

Meeting NotesMeeting G vantage points, and sparked additional connections and and connections additional sparked and points, vantage new from problems view and data to share opportunities provided we heard presentations excellent The G interactions. unexpected from comes science another,one best of the much as with to interact scientists forLudwig is it important how emphasized He of ideas. translation successful and collaboration innovation, to encourage routes best the to is identify mission His discoveries. of Ludwig potential the of maximizing goal the and mission core collective L MIT.Ludwig of Weinberg Bob of said researchers,” network worldwide of this goal amajor have been that collaborations the share science. are interactions These to critical inspiring roof and asingle under together sit could community Ludwig entire the years these all after that extraordinary “It’s patients. to cancer treatments new bringing and discoveriesis to critical paradigm-shifting making teamwork that understood Ludwig problems. toughest tothe solve minds best the together of bringing vision Ludwig’s K. of Daniel extension an was retreat the that L . of Van Ludwig Eynde den Benoît conversations to spark potential collaborations,” said forhallway and to bloom ideas fornew forum ideal an another. one with was It bridges build and bread break T think aboutpotential and collaborations. partnerships and science their alike, to share Centers the and Institute community, scientific Ludwig the across from researchers time first forthe together brought meeting The success. T

3 program and was the organizing force behind the retreat. the force behind organizing the was and program sciences collaborative the directs who Strausberg, Bob said acquaintances,” new and colleagues with discussions …an ideal forum ideal …an Benoît Van den Eynde collaborations. potential to spark conversations for hallway to bloom and for new ideas …opportunities …opportunities Bob Strausberg acquaintances. and new colleagues points…with vantage from new problems data and view to share

LUDWIG LINK | NOVEMBER 2013 udwig Oxford and and Oxford udwig cell’s you remove amature identity when happens hat “Understanding the dynamics of reprogramming and how how and of reprogramming dynamics the “Understanding Meeting NotesMeeting ABRACADABRA L bone marrow afterchemotherapy. replacing or tissue damaged forrepairing promise great holds therapy The type. cell adifferent from derived cells by normal replaced are cells defective which in therapy, in cell-replacement step afirst reprogramming, of cell? You anykind nuclear become get can it that so W next year in China and the United States. States. United the and China in year next attendees for the follow-up meetings follow-upmeetings forthe attendees conference. There was overwhelming among the support of the organizer an Oxford, of Ludwig Goding Colin in cancer,” opportunities therapeutic time identify said same the at and medicine, to regenerative impetus major a provide will effectively manipulated be can it learn about current research in the field. these disciplines and enable researchers to network and of similarities the to was highlight conference of the goal The fields. two these in of researchers panel international Cancer Genome, the conference brought together an Nature Genetics of editor Axton, Myles and Lu Xin between conversations of by aseries initiated was that University Oxford at Ludwig Oxford Liu Xin . Called Nuclear Reprogramming and the the and Reprogramming Nuclear . Called Nature co-hosted a conference aconference co-hosted

Ludwig Oxford Colin Goding Nature

is hosting hosting is 4 “Differentcancer immunotherapies aredesigned on focused company abiotech Design, mmune Company News Company coordinated CVC Trials Network. immunotherapy combinations through their jointly of cancer studies conduct will Institute Research Cancer the and Ludwig therapies.” of the likely impact the increasing fronts, multiple on cancer a patient’s of immunotherapy combinations enables us to hit scheduling safe and effective “Establishing program. development Ludwig’sSkipper, technology leads who components of the ,” said Jonathan to engage distinct and potentially complementary immunotherapies’cancer. against effectiveness to boost used adjuvant chemical asynthetic A, lipid glucopyranosyl and antigen, to adefined response an immunotherapy to designed stimulate immune LV305, are These Design’s pipeline. Immune from drugs of including two investigational immunotherapies, Cancer Research Institute to test novel combinations the and Ludwig with apartnership formed has diseases, therapies forimmune-based cancerand other human I WELL DESIGNED …enables us to hit a patient’s to a us hit …enables of therapies. the likelyincreasing the impact cancer on multiple fronts,

LUDWIG LINK | NOVEMBER 2013 udwig researchers in Melbourne, Matthias Australia, he findings reveal a surprising mutational signature of top the is cambogia Garcinia claims: e’ve the heard all News Roundup the two related proteins interleukin-11 andinterleukin-6. including molecules, different many produce and inflamed noncancerous or normal tissues around it can become the develops, atumor now. until When underestimated been had of interleukin-11 importance the that show 12 in August published astudy In worldwide. common most of the two cancers, bowel and of stomach treatment to the approach new an exciting have identified Tracy and Putoczki, Ernst L DARK HORSE largely unknown. In the latest study, the researchers remained it with associated of mutations spectrum wide genome- the toxin, plant to the exposed patients cancer tract urinary upper in mutations of the aware of some been had researchers Although inflammation. and gout for of thousands years to treat like ailments arthritis, remedies herbal in used been has that compound a plant acid, by aristolochic caused cancers tract urinary upper T cancers. tract urinary upper Medicine Translational Science of 7issue August the in published research, Their harm. even cause can they shows pharmacologists, University Stony Brook and Hopkins Johns of Ludwig Ken Kinzler by led experts, sequencing by genomic study anew fact, In andeffectiveness. studieson their safety medical few are valid there but tempting, is remedies herbal Taking cholesterol. lowers Flaxseed memory. improves Ginkgo colds. prevents Echinacea abottle. in burner fat W BEWAREBUYER Cancer Cell Cancer

, links herbal remedies to remedies herbal , links , the researchers researchers , the 5 enome-wide sequencing has allowed us to tie to us tie allowed has sequencing enome-wide “ and cells, of cancer spread the promote can nterleukin-6

spark aspark public health campaign. and prevention to cancer related decisions to guide data cancer.” necessary the provide will process Hopefully, this specific a causing for toxinis responsible aspecific that certainty with to say signature mutational recognizable the us gives cancer,” technology “The getting Ken. said individual to an directly exposure acid aristolochic G important,” Tracy said. very be fact in might it that shows now research new Our researchers. by cancer overlooked been often similar to interleukin-11 very being interleukin-6, has of cancer. development “Despite the in horse’ a ‘dark is of cancers, spread and growth the in role have aminor the team found that interleukin-11, which was thought to However, cancers. breast and kidney, prostate for ovarian, trials clinical in already are it block that agents anticancer I toxin. to the exposure suspected no with 7patients and acid, to aristolochic exposed been had who cancer tract urinary upper with 19 Taiwanese on patients sequencing whole-exome used Ken Kinzler Ludwig Johns Hopkins

LUDWIG LINK | NOVEMBER 2013 hey further discoveredhey further that blockinginterleukin-11 News Roundup T anticancer therapies. new to potential applied be might discovery the how to explore begun has team The cancers. of solid types many fortreating target new apromising it making shrinkage, to tumor lead might and growth tumor stopped cancer bowel and of stomach models in Ludwig Melbourne Ludwig Tracy Putoczki Melbourne Ludwig Matthias Ernst

…discovered …discovered cancers. of solid many types for treating new target it apromising making shrinkage, lead to tumor and might growth tumor stopped cancer and bowel of stomach in models interleukin-11 blocking that

6 eam of scientists led by Johan Holmberg at Ludwig Ludwig at Holmberg by Johan led of scientists eam euroblastoma accounts for 7 to 10 percent of childhood of childhood for7to 10percent accounts euroblastoma to tissue nervous healthy the in forcells necessary t is “ of cells the primitive the from arises euroblastoma

its tumorits suppressor capacity. previously unknown, as were the mechanisms underlying was development system nervous of normal CHD5 in role The cells. into cancer developing from cells healthy to prevent abrake as suppressor, acts a tumor which during normal nervous system development. CHD5 is of role CHD5 the at by looking children, young very in of cancer forms common most of the one neuroblastoma, have made a major breakthrough in understanding Dublin Trinity at College Bracken Adrian and A t DELETE DON’T benefit of reactivating CHD5 in neuroblastoma cells. cells. neuroblastoma in CHD5 of reactivating benefit plans to continue research its to assess the potential 12. team The DevelopmentalAugust Cell in on published were poor. is findings prognosis The the disease of the forms aggressive more with forpatients and cancers, N events.” cellular promoting cancer- additional with combination in especially cells, tumor dangerous yield might which state, immature an in locked become cells these capacity, this you lose “If Johan. to neurons,” cells explains stem from to go able be I cells. nerve into mature to specialize cells forstem required is of neuroblastoma forms malignant most the in ‘deleted’ is which CHD5, encoding gene the that discovered colleagues his and Johan instead. cells cancer become and to mature fail However, they neuroblastoma in cells. nerve into functioning mature growcells and peripheral nervous system. Normally, these immature N

LUDWIG LINK | NOVEMBER 2013 n the July 8 issue of the journal journal of the 8issue July n the amix include advanced tumors, ike other ICKLE FINGER CELL OF FATE the in Bond Gareth Oxford’s by Ludwig published tudy men in common most the is cancer esticular News Roundup protection against sun damage—think suntan. probably favored by it natural provides because selection was and people light-skinned in common is risk cancer mutationthe responsible same for increasing testicular Interestingly, of including cancers. variety diseases, awide of contracting risk with associated are some and DNA aperson’s throughout (SNPs), normally occur knownmutations, as single nucleotide polymorphisms that dramatically increase testicular These cancerrisk. F Preclinical studies show that the strategy, which employs resistance. sidestep and advanced to treat that manipulates a mechanism driving heterogeneity researcher strategy a therapeutic describes Colin Goding Oxford by Ludwig led of team scientists international I before. resistant drug become and return more aggressively than the success of melanoma-targeting many drugs, tumors off totumor. a kill Despite impossible it making therapies, targeted evade cells melanoma some help can differences These behaviors. and genetics different of with cells L of 10issue October A s ancestry. of African those than ancestry of European men in common more times five It’s 10,000 deaths. almost causes and over in 52,000 worldwide men diagnosed is disease the year 45. Each of 15 and ages the between T SN(I)PS Cell identifies a common mutation Cancer Cell Cancer , an , an 7 nowing the inherited genetics of cancer has great great has of cancer genetics inherited the nowing “ SNP aunique contains material genetic person’s ach

choices, thus improving management of the disease.” of the management improving thus choices, therapeutic inform and of cancers, likelyprognosis the It . also can particular tell physicians about of developing risk the to predict of tests development potential in medicine,” aid can the “It Gareth. said K cancer. against mechanism defense important cell’s the most is , which named protein of a activity the affects discovered team the SNP The map. genome human the on adisease pinpointing for markers biological as serve they Instead, state. foradisease responsible not are SNPs Most variations. genetic ofdifferent up many made is that pattern E he complexityhe of the against this disease. this against I think you have achance ways, different completely workin that therapies you give complementary work own. on its But if one therapy probably won’t disease is such that any T

LUDWIG LINK | NOVEMBER 2013 San of Ludwig Mischel by Paul led of researchers eam splicing the in achange through emerge can umors HE SPLICE LIFE OF of methotrexate, atreatment that found scientists he News Roundup T of EGFR, is present about half the time,” said Paul. time,” Paul. the half said about present is of EGFR, form mutant active oncogenic, an (EGFRvIII), III variant EGFR mutated those, Within EGFR. amplified of issue 4 June the in appeared study The metabolism. cellular making tumorsmore aggressive by reprogramming their c-Myc, partner binding of its function the enhances This Max. called protein of a splicing specific the induces in amplified (EGFR) often is receptor that factor growth epidermal of the avariant that found Diego A t adults. in tumors brain primary of malignant deadliest and (GBM), common most the new approaches therapeutic in glioblastoma multiforme of to arange lead might cells, healthy in activity normal and regulated atightly splicing, alternative controlling pattern of single gene. Understanding the factors T another. in metastases diminished and model mouse one in tumors suppressed to multiply. cells significantly It cancer signals that protein B-RAF of abnormal an action the blocks that adrug to vemurafenib, resistant tumors patient from derived cells on even It worked culture. in cells melanoma TMECG destroyed called efficiently anovel molecule with some other though cancers, not melanoma, combined a currently drug used to treat autoimmune diseases and T thateffective against tumors resist all therapies. other and cells melanoma to specific highly is chemotherapy, existing an with combination in molecule drug-like a new Cell Metabolism . “Just have an of GBMs half under

8 ancer cells are fickle, and some melanoma cells develop develop cells melanoma some and fickle, are cells ancer disease.” this against have chance a you think I ways, different give complementarytherapies that work in completely you if But own. its on won’t work probably therapy one any that such is disease of the complexity “The says. therapy,” cancer about Colin thinking be we should how is “This resistance. such around to get therapies cancer other with combined be can it that to show to novel therapy. have will Future research resistance C … Understanding Understanding multiforme. glioblastoma approaches in therapeutic a range of new to might lead ... splicing alternative controlling the factors Paul Mischel Ludwig San Diego

LUDWIG LINK | NOVEMBER 2013 n a paper published September 1 in 1in September published n apaper of organism’s all an hereditary contains genome he ATS, SHOOTS AND LEAVES EGFRvIII the whether werecurious scientists he News Roundup E been during development. had but active, longer no are that elements regulatory involve methylation DNA of tissue-specific regions some tissues, adult in that found they Totissue. surprise, their of kinds different in changes methylation DNA how on probe deeper into the mysteries of epigenetics, reporting Ren Bing and Hon Gary researchers Diego San Ludwig I of control. out grow wildly that cells cancer into cells normal converting havoc, wreak can they cell, wrong the in or time wrong the at occur changes If such on. or off growth cell involved in genes switch can groups methyl removing or Adding activity. gene to oversee use cells mechanisms epigenetic of the one just represent groups Methyl orders. marching their cells gives this and pattern, methylation adistinct has cell Every methylation. DNA through is this way does it One bodies. our in cells different in expressed are genes some whether or thechange epigenome our determines DNA, how much doesn’t it Although punctuation. its be would epigenome information. If the genome were a paragraph, the T in tumors. metabolism cellular altering in role its and GBM in ofrole EGFRvIII central the highlight and GBMs, and mutation EGFRvIII the to arespecific findings The forgrowth. used be can that blocks of building asource and of energy supply asufficient both provides away in that glucose metabolize to cells tumor enables which Warburg Effect, the on focused They metabolism. cellular of normal deregulation to led that events splicing alternative induced mutation T Nature Genetics , 9 development,” of understanding our help findings hese “

action to prevent them.” take can science before step necessary life—a developing in early occur that of diseases origins the understanding to helpful be may they term, long the “In Gary. said T f the genome were a would be its punctuation. its would be paragraph, the epigenome I

LUDWIG LINK | NOVEMBER 2013

Ask aScientistAsk to the ‘war’ on cancer today? What is the biggest obstacle dwig YRON BURNETTE cancer on ‘war’ the in obstacles biggest of the ne Diego San udwig ILL WYKOSKY multidisciplinary, true will require cancer against ictory Uppsala udwig MORIKAWA ASATO and are heterogeneous cancers is normal: bnormal Lu B are targeting. cells they cancer the as asadaptable are just that solutions innovative develop and tumor. heterogeneity this same to embrace We need the cells within cancer between and tumors, between is heterogeneity. Heterogeneity between individuals, O L J patients. to benefit drugs of better feat design will this allow for the Accomplishing genomics. as such technologies advancing rapidly from information new with of cancer knowledge basic our integrating collaborativeThe biggest obstacle efforts. today is A v L M and treatment strategies. classification to disease will contribute status mutation to determine methods easy and nature. Cheap true their understand and defects the to characterize necessary will be tumor each in mutations of the screening Genome-wide mutations. driver many accumulate A

10

LUDWIG LINK | NOVEMBER 2013 his was exciting because Montana didn’t Montana because his was exciting a reading after 10 at age as hooked ascientist? youow become did Q&A with Irv Weissman withIrv Q&A construct and do my own experiments. my do own experiments. and construct something invaluable — the freedom to Dr. roll. But honor the Eichwald gave me made never who school high local the in aB+ Iwas just knew never student He student. like was treated agraduate and his lab in assistant aresearch I became $25 on Weamonth. for free. work settled I’d Isaid until went nowhere conversation our and accent German athick spoke with and deaf was partially He forhim ajob. Iasked So school. even have amedical T Falls, of Great my hometown Montana. is which in institute, Research McLaughlin the now Hospital, Deaconess to the lab and his practice moved and academia of biology. was tired He transplantation in was aspecialist who a pathologist Eichwald, Ernst with school high in junior asa career my scientific began and to do Iwanted what that’s then I knew of facts. memorization mere to the dedication, and investigation as opposed an individual researcher’s imagination, that medical knowledge comes from demonstrated He lives. and stories their Koch, interweaving Robert and like Pasteur scientists by important made Michigan. He described the discoveries of University at the Kruif, apathologist Microbe Hunters called book I w H Great man from Great Falls by Paul De by De Paul et’s start with a genetic disease we’ve disease agenetic with et’s start you’ve stories success some you share an Ludwig Stanford coma and inevitably dies. They’re unable to They’re unable dies. inevitably and coma into a goes then thinking, then balance, then sight, to lose starts disease the gets who Achild cells. nerve in toxic product of a buildup the in results that children a fatal neurodegenerative disorder in disease, Batten called on working been L therapies? cell stem with had C work. things how about write or say people other what memorize than rather work things how out to figure me for career. important more It’s been always my Itshaped is really obtained. information how To understand and about think Weissman Irv

11 t’s always people say. people what other memorize rather than work things figure how out for to me important morebeen I

LUDWIG LINK | NOVEMBER 2013 n another trial in 2011, these human human 2011, in these trial n another I acompany Cells Inc., Stem n 2006, Q&A are all forming oligodendrocytes and we and oligodendrocytes are all forming cells stem transplanted the with treated we disorder,a similar four patients the with mice deficient immune the in As death. early to an leading deterioration undergo progressive neurological They breathing. have trouble often and talk, to walk or ability the develop oligodendrocytes and therefore don’t don’t kids make These cells. nerve along efficiently and quickly to transmit forms around and allows nerves impulses layer that insulating myelin, the making from oligodendrocytes cells called brain prevents that defect genetic inherited PMD. or disease It’s an Merzbacher asPelizaeus- known of acondition form fatal early-onset, an with children of four young brains into the directly were injected cells we developed neural I disease. of the course expected the alive beyond are still disease of the stage mildest the with ones The process. recycling cell- the to reset cells, progenitor and stem cell-derived stem neural human purified with them involved infusing that patients six with atrial did co-founded, I to celldeath. leading eventually bursting the lysosomes and system, recycling and disposal garbage like a act that lysosomes cells called the in up builds waste cellular the enzyme, the Without substances. waste cellular produce enough of an to enzyme process e found that aCD47-blocking that e found research on is based his breakthrough Testse likeso. immune to think on you CD47-blockings the antibody higher levels of CD47 than healthy cells levels of healthy CD47higher than cells have cancer other and leukemia all Wehuman that cells. found also cancer macrophages to recognize and engulf system immune the by enabling leukemia of cases cure some could antibody W tested. we all cancers and leukemia all human supply. CD47 we found But blood on arefreshed cells and blood red younger way for making cells, blood red aging tothe eat of CD47 macrophages allows dearth the level, acertain At age. as they protein the slowly lose and cell surface alot of CD47 with out their on cells start blood Red cells. blood red on marker age asan CD47 acts cellsurface. the on CD47 was expressed that called protein levels of a high cells and stem leukemia between we alink discovered when at Stanford here ago 15 years began that T year. next early therapy cancer of the trial Iclinical aphase to begin now,data Right have enough we effects. side- minimal with of cancers range abroad on works it cells showed cancer patient with transplanted mice deficient W developed really a wonder drug? I generated fresh myelin. they’ve indicating evidence have imaging 12 o into famous. become or make money the field to Don’t get into results ... the seeing love you because science G

LUDWIG LINK | NOVEMBER 2013 atistically an industry that harvests harvests that industry an atistically a from yourself to save ’s like trying Ifyou have agenetic not. robably a‘bank’ use person average the hould CD47 the ‘don’tlocking me’ eat signal Q&A that it prevents those cord bloods being being cord bloods those prevents it that extent to the And utility. no has almost has public general away the from banks private in them holds and cord blood St the other ones. Not You cells. sense. stem healthy need make doesn’t alot of for yourself yourself cells from getting So disease. Gehrig’s Lou asin genes multiple but gene a single to are due not diseases genetic many And have. you already that disease genetic It deficient. immune be will bloods cord the deficiency, Ifyou have immune an disease. genetic same will have the cordyour bloods and disorder,blood at birth it’s present or cancer for acertain disposition P someday? lives save their possibly and organs to grow replacement used be may they abet in cells own stem to their store S human therapy. cancer for target promising and legitimate CD47 that is a demonstrates I think which we tested, cancer human every of nearly mice in growth the inhibited B into not destroying them. system immune the trick effectively can cells by cancer CD47 the produced and ick to your guns. Push to translate your your to translate Push guns. ick to your you ever received advice best the hat’s nowledge is obtained through you love seeing because o into science you have do people for advice hat as ascientist? as it. That was from my mentor at Stanford, at Stanford, my was from mentor That it. to do else —don’t it fordo wait someone away to Find clinic. into the discoveries St W overcome them? I can how and discovery this to translating barriers are the what yourself Ask it. from translational that opportunities come to potential forward make sure you look you make adiscovery, Once discoveries. your Take for translating responsibility experiment. an to design opportunity asan paper at every Look experiments. K that. to do ways There’re alot of easier famous. become or make to money field intoget the Don’t own your observations. and ideas own your from come that results the G field? the entering W siblings. matched have not do who for people are lifesaving they where banks, cord blood available publicly into the HSC blood peripheral mobilized eventually and cord bloods, place be to should effort appropriate The lives. other of saving possibility the back you’re else a match somewhere holding accessible to who somebody doesn’t have 13

tick to your a way to do it. the clinic. Find discoveries into translate your to Push guns. S

LUDWIG LINK | NOVEMBER 2013 his led me and others to champion to champion others and me his led identify to first 1980s we were the n the with involvement your ow did Q&A value could be tested and appreciated. appreciated. and tested be could value commercial and clinical their where trials, clinical phase early through to and them advancing and discoveries stem-cell new in of bringing hope the with Medicine of Regenerative Institute California the created which 71, Proposition T researchers. of biomedical goals clinical match not the may pharma of big goals commercial —the lesson abig learned we But down. were shut cell programs stem- —the later four years And pharma. by abig was purchased which SyStemix, acompany, Iformed So cell. stem a single evenfrom celltypes, makealso all blood self-renew could and they proved that We humans. in later and mice in first cells, stem forming blood mouse isolate and I about? come 71 Proposition H them. with to do what didn’t me tell and my ideas out to try lab a evengave me He degree. my medical receiving after science in to stay decided I when road right the Iwas on me told who one only was the He Kaplan. Henry he 2001 Bush policy on stem-cell stem-cell on policy Bush 2001 he capital and big pharma now avoid. now pharma big and capital venture both that risks the having without trials clinical through discoveries advance way —anew to voters California by the legacy enduring an will be this I hope forsupport stem-cell embryonic research. federal full toward enabling step is amajor This 2008. in by Obama by proclamation, and, 2004 in California in 71 of Proposition passing the with was overturned research T 14 he world’s first beef patty patty beef first world’s he 325,000, USD awhopping or ‘ ark Post, the Dutch scientist scientist Dutch the Post, ark

Frankenburger’: in 2035 — or not. 2035 —or in dinner for what’s be may It no bun. no fanfare — but no ketchup and much with August past this London in eaten and cooked was cells stem from grown Meal. aHappy inside tucked figure action an least very the at Or ashake. and fries with come to it expect might you DID YOU KNOW… for animal welfare. concern of his because project the funded he said who Google of acofounder Brin, Sergey is deep-pocketed mystery backer burger’s The start.” agood it’s but perfect, not “It’s said, he testing taste the After cheese. favorite topping, aged gouda his without patty the served having regretted cells, stem cattle from delight culinary the grew that team the led who T F M

LUDWIG LINK | NOVEMBER 2013 ancer Research Lausanne udwig ancer Research Translationalcience Medicine Required Reading Corgnac S, Donda A, Romero P. Romero A, Donda S, Corgnac NK, Botelho S, Sierro R, Perret tumor immunity to regulatory T cells enhance effector antigen-specific of Adjuvants that improve the ratio print) of ahead (Epub 18 2013 September C L GJ. Riggins CG, Eberhart AJG, Simpson RL, Strausberg P, Burger H, Brem A, Olivi A, Quinones-Hinojosa GL, V, Gallia Salmasi ZA, T, Binder Cohen Q, S.Y. JSY, Janelle Ho Zhao OL, Caballero GS, Baia S, Gilson C TA. Rosenquist KW, AP, Kinzler Grollman N, YS, Vogelstein B, Papadopoulos Pu RJ, Turesky R, C, Karchin Douville N, Niknafs M, Moriya YunBH, KG, J,Dickman He VS, Sidorenko CH, Chen ML, Hoang S Ludwig Johns Hopkins sequencing whole-exome by revealed as aristolochic acid exposure Mutational signature of 7 2013 August immunotherapeutic approaches new for a rationale meningioma suggests in expression NY-ESO-1 print) of ahead (Epub 5 2013 August

ancer Cell Oxford dwig ancer Immunology Research York New udwig ancer Cell udwig Melbourne C Lu C L C L McKenzie BS, Ernst M. Ernst BS, McKenzie FR, Greten A, BT, Nash Kile I, Pleines OM, Sieber JK, Heath A, D, Boussioutas Horst A, Jarnicki RB, Y, Luwor Boglev KM, Edwards R, Farid A, Preaudet PM, Nguyen PK, Ziegler NJ, Wilson RA, Busuttil A, Loving S, Thiem TL, Putoczki therapeutically targeted be can and gastrointestinal tumorigenesis family cytokine duringIL-6 Interleukin-11 is the dominant 122013 August Goding CR, JN. Rodríguez-López J, Cabezas-Herrera A, Madrona Freter R, Middleton M, Piñero- S, MP, Chazarra Fernández-Pérez L, MF, Sánchez-Del-Campo Montenegro M, Sáez-Ayala strategy antimelanoma effective an as Directed phenotype switching 2013 8 July JD, Wolchok JD. Wolchok JD, Yuan S, JP, Gnjatic Allison Z, Mu D, C, Kyi Hirschhorn-Cymerman T, C, Tsuji S, Liu Kitano patients melanoma advanced four in after ipilimumab treatment responses Tcell CD4+ cytotoxic Enhancement of tumor-reactive 122013 August

15 dwig Sandwig Diego ature ell Metabolism Cleveland DW. LE, Jansen A, Desai AJ, Holland Q, Zhu AJ, Wong K, Nguyen Y, ValenteNechemia-Arbely LP, H, Folco D, Diego Fachinetti and function of centromere identity for epigenetic specification mechanism A two-step 182013 August Bond GL. Bond DA, Bell S, Val De N, Meinshausen T, P. IP, Ian NF, Tomlinson Box Terzian GJ, Walker N, Sacilotto EFP, Peterse B, F,Giner Davies Castro- Su, Dan MR, Campbell E, Repapi X, J,Wang Zeron-Medina natural selection cancer risk and has undergone element in KIT ligand influences response p53 A polymorphic 102013 October Lu Cell N C Black DL, Mischel PS. Black DL, HR, TF, Christofk Cloughesy WK, SF, Cavenee Yong WH, Nelson A, Eskin SK, Kurdistani CE, Camacho R, Li S, Mareninov B, D, Gini D, Nathanson Akhavan GR, Y, Villa Gu S, Zhu B, Li K, D, Masui Guo K, Tanaka ES, Anderson I, Babic tumorsglycolytic in brain cancer of growth to contributes max of splicing alternative EGFR mutation-induced 2013 4 June

tem Cell Reports Stanford dwig ure Genetics evelopmental Cell Stockholm udwig Ren B. Ren DF, YueF, MD, Dang McCleary Y, Shen N, Rajagopal GC, Hon adult mouse tissues from maps methylation DNA in embryonic enhancers identified Epigenetic at memory 1 2013 September H, Weissman IL. Weissman H, CKF, Nakaushi Chan S, JY, Karten J,Chen Y, Seita Mori M, Miyanishi embryonic stem cells? in adult mice as very small Do pluripotent stem cells exist 6 2013 August S Lu Nat D L rce P. A Bracken J, Holmberg K, Helin GJ, Farrar K, Hansen N, Chadderton MJ, V, Dolan Rraklli DJ, Streubel G, Turner S, O’Connell J, U, Skotte Nyman CM, Egan polycomb gene repression gene expression and a dual role in facilitating has and neurogenesis for required is CHD5 122013 August

LUDWIG LINK | NOVEMBER 2013